Cosciens Biopharma(OTC) CSCIF

Market Cap$6.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-100%
5 Year-97%
1 Year-21%
1 Month+29%
$6.44
+0.31%
+0.02Today
Cosciens Biopharma last closing stock price
MetricPriceDate
Last closeUSD 6.442026-10-05
Cosciens Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.31%USD 6.462026-09-28
1 month+29.32%USD 4.982026-09-04
3 month-8%USD 7.002026-07-07
Year to date+4.21%USD 6.182025-12-31
1 year-20.57%USD 8.112025-10-03
3 year-73.85%USD 24.632023-10-06
5 year-96.5%USD 184.022021-10-06
Since inception-100%USD 1,912,484.702000-05-10

Cosciens Biopharma Financials at a Glance

Market Cap

$6.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$8.28

Net Income (TTM)

-$4.39

EPS (TTM)

-$4.48

P/E Ratio

-1.44

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$6.44

Volume

1

Open

$6.44

Previous Close

$6.44

Daily Range

$6.44 - $6.44

52-Week Range

$2.37 - $9.57

Estimated Earnings Date

N/A

CSCIF News

Tackling Cancer: Your Best Investing Ideas

Sean WilliamsJun 1, 2013
Endometrial cancer

Tackling Cancer: Endometrial Cancer's Biggest Current and Upcoming Players

Sean WilliamsMay 11, 2013

Aeterna Zentaris Names New CEO

Eric VolkmanApr 15, 2013

This Week in Biotech

Sean WilliamsMar 16, 2013

Breakdown of This Biotech Massacre

Dave WilliamsonMar 11, 2013

Will the Feuerstein-Ratain Rule Hold in 2013?

Maxx ChatskoJan 18, 2013
oprhan drugs

Do Orphan Drug Developers Belong in Your Portfolio?

Sean WilliamsJan 15, 2013

This Week in Biotech

Sean WilliamsJan 5, 2013
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cosciens Biopharma

Æterna Zentaris, Inc. is a specialty biopharmaceutical company, which engages in the development and commercialization of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Industry

Biotechnology

Sector

Health Care

Employees

28

CEO

Peter Harry Puccetti, CFA

Website

www.cosciensbio.com

CSCIF Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-39.99%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-69.44%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$6.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

996.40K

Volume

1

Avg. Volume

703.272

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Cosciens Biopharma Performance Analysis

Cosciens Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 5,640,0007.2%
20232023-12-31USD 7,143,00026.6%
20242024-12-31USD 9,587,00034.2%
20252025-12-31USD 7,498,000-21.8%
Cosciens Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -56.16157.1%
20232023-12-31USD -22.64-59.7%
20242024-12-31USD -17.79-21.4%
20252025-12-31USD -9.82-44.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$3.14

+1.1%

Gross Profit

$1.74

+1.8%

Gross Margin

55.27%

+1.6%

Market Cap

$6.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$0.26

N/A

Employees

28

N/A

Net Income

-$0.20

+0.1%

EBITDA

$0.76

-0.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$7.23

-37.6%

Total Debt

$1.96

+0.9%

Accounts Receivable

$2.37

+0.9%

Inventory

$0.96

+0.5%

Long Term Debt

$1.77

+0.9%

Short Term Debt

$0.19

+0.9%

Return on Assets

-18.91%

+0.4%

Return on Invested Capital

-74.95%

+1.6%

Free Cash Flow

$0.60

-0.1%

Operating Cash Flow

$0.61

-0.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,828.74+0.01%
^DJIDJI
$51,532.64+0.01%
^IXICNASDAQ
$27,658.12+0.01%
BTCBitcoin
$85,726.00+0.00%

Questions About CSCIF

What is the current price of Cosciens Biopharma?

Cosciens Biopharma is trading at $6.44 per share.

What is the 52-week range for Cosciens Biopharma?

Over the past 52 weeks, Cosciens Biopharma has traded between $2.37 and $9.57.

How much debt does Cosciens Biopharma have?

As of the most recent reporting period, Cosciens Biopharma reported total debt of $1.96M.

How much cash does Cosciens Biopharma have on hand?

Cosciens Biopharma reported $5.28M in cash and cash equivalents in its most recent financial results.

What is Cosciens Biopharma’s dividend yield?

Cosciens Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services